<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857517</url>
  </required_header>
  <id_info>
    <org_study_id>TJMUEH001</org_study_id>
    <nct_id>NCT02857517</nct_id>
  </id_info>
  <brief_title>Intravitreal Conbercept for Idiopathic Choroidal Neovascularization</brief_title>
  <official_title>Intravitreal Conbercept for Idiopathic Choroidal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiao Mingfei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Eye Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular&#xD;
      endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at one day after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at one week after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at four weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>Change from Baseline visual acuity at eight weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at 12weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at half year after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity(Snellen chart)</measure>
    <time_frame>Change from Baseline visual acuity at 1 year after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness(OCT)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness</measure>
    <time_frame>Change from Baseline macular central fovea thickness at four weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness(OCT)</measure>
    <time_frame>Change from Baseline macular central fovea thickness at eight weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness(OCT)</measure>
    <time_frame>Change from Baseline macular central fovea thickness at 12 weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness(OCT)</measure>
    <time_frame>Change from Baseline macular central fovea thickness at half year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular central fovea thickness(OCT)</measure>
    <time_frame>Change from Baseline macular central fovea thickness at 1 year after injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Idiopathic Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>intravitreal 0.05ml conbercept for ICNV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05ml conbercept ,1 injection with PRN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conbercept</intervention_name>
    <description>0.05ml conbercept</description>
    <arm_group_label>intravitreal 0.05ml conbercept for ICNV</arm_group_label>
    <other_name>conbercept fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who give voluntary signed informed consent&#xD;
&#xD;
          -  Patient affiliated with the Tianjin Medical University Eye Hospital or similar&#xD;
&#xD;
          -  Patient with ICNV with active primary subfoveal, retrofoveal or juxtafoveal lesions&#xD;
             that affect the fovea as evidenced by angiography (fluorescein and/or indocyanin&#xD;
             green) and/or SD-OCT in the studied eye&#xD;
&#xD;
          -  Patient willing, committed and able to return for all clinic visits and complete all&#xD;
             study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Sexually active men or women of childbearing potential who are unwilling to practice&#xD;
             adequate contraception during the study&#xD;
&#xD;
          -  Patient who is protected adults according to the terms of the law (French public&#xD;
             health laws)&#xD;
&#xD;
          -  Involvement in another clinical trial (studied eye and/or the other eye)&#xD;
&#xD;
          -  Patient with non-ICNV, especially:&#xD;
&#xD;
               -  AMD&#xD;
&#xD;
               -  High myopia defined as refraction ≥ - 6 diopters&#xD;
&#xD;
          -  Other curative treatment of ICNV in the studied eye during the last 3 months before&#xD;
             the first intravitreal injection: anti-VEGF therapy, juxta- or extra-foveal macular&#xD;
             laser, photodynamic therapy, surgery, external radiotherapy, transpupillary&#xD;
             thermotherapy ...&#xD;
&#xD;
          -  Medical history of retrofoveal focal macular laser photocoagulation in the studied eye&#xD;
&#xD;
          -  Subretinal haemorrhage reaching the fovea centre, with a size &gt; 50% of the lesion area&#xD;
&#xD;
          -  Fibrosis or retrofoveal retinal atrophy in the studied eye&#xD;
&#xD;
          -  Retinal pigment epithelial tear reaching the macula in the studied eye&#xD;
&#xD;
          -  Medical history of intravitreal medical device in the studied eye&#xD;
&#xD;
          -  Medical history of auto-immune or idiopathic uveitis&#xD;
&#xD;
          -  Proved diabetic retinopathy&#xD;
&#xD;
          -  Intra-ocular pressure ≥ 25 mmHg despite two topical hypotonic treatments&#xD;
&#xD;
          -  Aphakia or lack of lens capsule (not removed by YAG laser) in the studied eye&#xD;
&#xD;
          -  Arterial hypertension that is not controlled by an appropriate treatment&#xD;
&#xD;
          -  Previous or actual treatment with systemic administration of anti-VEGF therapy&#xD;
&#xD;
          -  Known hypersensitivity to aflibercept, or another drug composite of the medicinal&#xD;
             product used; allergy to fluorescein, indocyanin green, anaesthetic eye drops&#xD;
&#xD;
          -  Active or suspected ocular or peri-ocular infection&#xD;
&#xD;
          -  Serious active intra-ocular inflammation in the studied eye&#xD;
&#xD;
          -  Medical history of intra-ocular surgery within 28 days before the first injection in&#xD;
             the studied eye&#xD;
&#xD;
          -  Any illness or ocular condition that would require an intra-ocular surgery in the&#xD;
             studied eye within 12 months after the inclusion&#xD;
&#xD;
          -  Follow up not possible during 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingfei Jiao, master</last_name>
    <phone>18630956101</phone>
    <email>jiaomingfei2004@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300384</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingfei Jiao</last_name>
      <phone>18630956101</phone>
      <email>jiaomingfei2004@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University Eye Hospital</investigator_affiliation>
    <investigator_full_name>Jiao Mingfei</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

